Yoseph Shaaltiel, Executive VP, R&D at Protalix BioTherapeutics, Inc. (PLX), sold 100,000 shares at $9.39 ($941K) on 2009-10-16, disclosed to the SEC on 2009-10-19.
Scheduled sale ($941k) by Executive VP, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.39 | 31,200 | $293K | 31.1% |
| 2 | $9.39 | 25,680 | $241K | 25.6% |
| 3 | $9.43 | 43,120 | $407K | 43.2% |
| Total | $9.41 avg | 100,000 | $941K | 100% |
| Filing → |
| PLX | SELL | 2010-06-23 | $371K | — | Filing → |
| PLX | SELL | 2010-05-03 | $89K | — | Filing → |
| PLX | SELL | 2010-04-16 | $9K | — | Filing → |